PMC:7463108 / 83492-83749 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T801","span":{"begin":4,"end":8},"obj":"Body_part"},{"id":"T802","span":{"begin":170,"end":173},"obj":"Body_part"},{"id":"T803","span":{"begin":213,"end":223},"obj":"Body_part"},{"id":"T804","span":{"begin":232,"end":241},"obj":"Body_part"}],"attributes":[{"id":"A801","pred":"fma_id","subj":"T801","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A802","pred":"fma_id","subj":"T802","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A803","pred":"fma_id","subj":"T803","obj":"http://purl.org/sig/ont/fma/fma54537"},{"id":"A804","pred":"fma_id","subj":"T804","obj":"http://purl.org/sig/ont/fma/fma68923"}],"text":"The cell type specific interactions between CCR5 and MOR were noted when using a bivalent ligand derivative of maraviroc linked to an opioid antagonist, naltrexone, with HIV-1 entry being significantly blocked in astrocytes but not microglia (El-Hage et al."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T863","span":{"begin":4,"end":13},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T864","span":{"begin":79,"end":80},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T865","span":{"begin":213,"end":223},"obj":"http://purl.obolibrary.org/obo/CL_0000127"},{"id":"T866","span":{"begin":232,"end":241},"obj":"http://purl.obolibrary.org/obo/CL_0000129"}],"text":"The cell type specific interactions between CCR5 and MOR were noted when using a bivalent ligand derivative of maraviroc linked to an opioid antagonist, naltrexone, with HIV-1 entry being significantly blocked in astrocytes but not microglia (El-Hage et al."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T17870","span":{"begin":90,"end":96},"obj":"Chemical"},{"id":"T86945","span":{"begin":111,"end":120},"obj":"Chemical"},{"id":"T279","span":{"begin":134,"end":151},"obj":"Chemical"},{"id":"T83127","span":{"begin":141,"end":151},"obj":"Chemical"},{"id":"T281","span":{"begin":153,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A98837","pred":"chebi_id","subj":"T17870","obj":"http://purl.obolibrary.org/obo/CHEBI_52214"},{"id":"A11785","pred":"chebi_id","subj":"T86945","obj":"http://purl.obolibrary.org/obo/CHEBI_63608"},{"id":"A85740","pred":"chebi_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/CHEBI_60605"},{"id":"A9666","pred":"chebi_id","subj":"T83127","obj":"http://purl.obolibrary.org/obo/CHEBI_48706"},{"id":"A71279","pred":"chebi_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/CHEBI_7465"}],"text":"The cell type specific interactions between CCR5 and MOR were noted when using a bivalent ligand derivative of maraviroc linked to an opioid antagonist, naltrexone, with HIV-1 entry being significantly blocked in astrocytes but not microglia (El-Hage et al."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2937","span":{"begin":44,"end":48},"obj":"Gene"},{"id":"2938","span":{"begin":53,"end":56},"obj":"Gene"},{"id":"2949","span":{"begin":246,"end":250},"obj":"Gene"},{"id":"2950","span":{"begin":170,"end":175},"obj":"Species"},{"id":"2955","span":{"begin":153,"end":163},"obj":"Chemical"}],"attributes":[{"id":"A2937","pred":"tao:has_database_id","subj":"2937","obj":"Gene:1234"},{"id":"A2938","pred":"tao:has_database_id","subj":"2938","obj":"Gene:4988"},{"id":"A2949","pred":"tao:has_database_id","subj":"2949","obj":"Gene:55510"},{"id":"A2950","pred":"tao:has_database_id","subj":"2950","obj":"Tax:11676"},{"id":"A2955","pred":"tao:has_database_id","subj":"2955","obj":"MESH:D009271"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The cell type specific interactions between CCR5 and MOR were noted when using a bivalent ligand derivative of maraviroc linked to an opioid antagonist, naltrexone, with HIV-1 entry being significantly blocked in astrocytes but not microglia (El-Hage et al."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1129","span":{"begin":0,"end":257},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The cell type specific interactions between CCR5 and MOR were noted when using a bivalent ligand derivative of maraviroc linked to an opioid antagonist, naltrexone, with HIV-1 entry being significantly blocked in astrocytes but not microglia (El-Hage et al."}